Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity.
Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, Schmachtenberg JL, Schutzer KA, Schutzer WE, Janowsky A, Abbas AI. Kozell LB, et al. Among authors: schmachtenberg jl. J Pharmacol Exp Ther. 2024 Apr 18;389(2):219-228. doi: 10.1124/jpet.123.002052. J Pharmacol Exp Ther. 2024. PMID: 38453524 Free PMC article.
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
Ofori E, Onyameh EK, Gonela UM, Voshavar C, Bricker B, Swanson TL, Eshleman AJ, Schmachtenberg JL, Bloom SH, Janowsky AJ, Ablordeppey SY. Ofori E, et al. Among authors: schmachtenberg jl. Eur J Med Chem. 2021 Mar 15;214:113243. doi: 10.1016/j.ejmech.2021.113243. Epub 2021 Feb 3. Eur J Med Chem. 2021. PMID: 33582388 Free PMC article.
A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder.
Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu ES, Friedman J, Lam J, Rais R, Reed JF, Bloom SH, Swanson TL, Schmachtenberg JL, Eshleman AJ, Janowsky A, Xi ZX, Newman AH. Galaj E, et al. Among authors: schmachtenberg jl. Neuropsychopharmacology. 2022 Dec;47(13):2309-2318. doi: 10.1038/s41386-022-01379-1. Epub 2022 Jul 25. Neuropsychopharmacology. 2022. PMID: 35879349 Free PMC article.
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter.
Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, Olson RJ, Janowsky A, Abbas AI. Kozell LB, et al. Among authors: schmachtenberg jl. J Pharmacol Exp Ther. 2023 Apr;385(1):62-75. doi: 10.1124/jpet.122.001454. Epub 2023 Jan 20. J Pharmacol Exp Ther. 2023. PMID: 36669875 Free PMC article.
Enantiomeric Separation, Absolute Configuration by X-ray Crystallographic Analysis, and Functional Evaluation of Enantiomers of the Dual Ligand, SYA0340 at 5-HT1A and 5-HT7A Receptors.
Bricker BA, Voshavar C, Onyameh EK, Gonela UM, Lin X, Swanson TL, Kozell LB, Schmachtenberg JL, Bloom SH, Janowsky AJ, Ablordeppey SY. Bricker BA, et al. Among authors: schmachtenberg jl. ACS Omega. 2023 Jun 7;8(24):21736-21744. doi: 10.1021/acsomega.3c01283. eCollection 2023 Jun 20. ACS Omega. 2023. PMID: 37360419 Free PMC article.